Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinniuer is a topical combination ointment containing the high-potency corticosteroid clobetasol propionate and the retinoid tretinoin (all-trans retinoic acid). It is primarily indicated for the treatment of chronic plaque psoriasis (psoriasis vulgaris). Clobetasol propionate provides potent anti-inflammatory, antipruritic, and immunosuppressive effects by activating glucocorticoid receptors, which leads to the inhibition of inflammatory cytokines and mediators. Tretinoin acts on retinoic acid receptors (RARs) to normalize keratinocyte proliferation and differentiation, which helps reduce the scaling and thickness of psoriatic plaques. The combination is designed to improve therapeutic outcomes compared to monotherapy while potentially reducing the risk of skin atrophy associated with potent corticosteroids. Jinniuer is manufactured by Chongqing Huabang Pharmaceutical and is widely used in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clobetasol propionate + tretinoin.